Metformin Drug Review: What PTCB Techs Must Know

Metformin Overview for the PTCB Exam

Metformin is the most widely prescribed oral medication for type 2 diabetes and consistently appears on the PTCB certification exam. As the first-line pharmacological treatment for diabetes, pharmacy technicians must understand its properties, dosing, and safety considerations. This review will prepare you for metformin-related questions on the 90-question PTCB exam.

Brand Name and Classification

Metformin is sold under the brand name Glucophage. An extended-release formulation is available as Glucophage XR. Metformin belongs to the biguanide drug class and is the only biguanide currently available in the United States.

Mechanism of Action

Metformin works through several mechanisms to lower blood glucose. It primarily decreases hepatic glucose production and increases insulin sensitivity in peripheral tissues, particularly skeletal muscle. Unlike sulfonylureas, metformin does not stimulate insulin secretion, which means it carries a very low risk of hypoglycemia when used as monotherapy.

Common Indications

Type 2 diabetes mellitus: First-line treatment per ADA guidelines
Prediabetes: Used off-label for diabetes prevention
Polycystic ovary syndrome (PCOS): Off-label use to improve insulin resistance

Dosing Information

Metformin immediate-release tablets are available in 500 mg, 850 mg, and 1000 mg strengths. The typical starting dose is 500 mg twice daily or 850 mg once daily with meals, titrated gradually to reduce GI side effects. The maximum daily dose is 2,550 mg for immediate-release and 2,000 mg for extended-release formulations. Metformin should always be taken with food to minimize gastrointestinal upset.

Side Effects

The most common side effects are gastrointestinal and typically improve over time:

Nausea, vomiting, and diarrhea: Most frequent complaints
Abdominal discomfort and bloating: Usually dose-related
Metallic taste: Reported by some patients
Vitamin B12 deficiency: Long-term use may reduce B12 absorption
Lactic acidosis: Rare but serious, especially in patients with renal impairment

Contraindications and Precautions

The most critical contraindication tested on the PTCB exam is severe renal impairment (eGFR below 30 mL/min). Metformin should also be temporarily discontinued before iodinated contrast procedures due to the risk of acute kidney injury and subsequent lactic acidosis. Patients should hold metformin for 48 hours before and after contrast administration.

PTCB Exam Tips

High-yield facts: metformin is brand name Glucophage, it is the only biguanide, it has a low hypoglycemia risk as monotherapy, the black box warning is for lactic acidosis, and it must be held for contrast dye procedures. These facts are commonly tested on the PTCB exam.

Strengthen your drug knowledge with our Top 200 Drugs flashcards and practice exams at PTCBprep.